Contact us
Menu
Contact us
BCC

Basal Cell Carcinoma (BCC) at a Glance

BCC is the most common form of skin cancer, and the most common type of all cancers.  

 
Basal Cell Carcinoma

Affects 3.6 million people each
year in North America

Basal Cell Carcinoma

Primarily caused by 
cumulative sun exposure 

Basal Cell Carcinoma

Most commonly develops on
sun exposed areas such as the
face, neck, and scalp 

Basal Cell Carcinoma

There remains a need for treatments
that preserve skin, minimize
discomfort, and allow patients
to return to their daily lives promptly 


BCC Subtypes and Treatments

BCCs start in basal layer of the skin and can appear in different forms depending on how they grow within the skin layers. 

Superficial BCC (≈15% of cases) 
Usually treated with topical medications, such as creams, applied directly to the skin. 

Advanced or Metastatic BCC (≈1-10% of cases) 
Treated with systemic therapies such as Hedgehog pathway inhibitors, or surgery. 

Nodular BCC (≈60-80% of cases)  
Mostly treated with surgical excision, including Mohs surgery, which is often referred to as the gold standard.

Skin Layers


Understanding Nodular BCC Care 

Mohs surgery is widely considered the gold-standard surgical technique for nodular basal cell carcinomas (nBCC), particularly when located in cosmetically sensitive or high-risk areas. The procedure involves removing thin layers of skin one at a time and examining each layer microscopically until no cancer cells remain.

While Mohs surgery is effective, it is a surgical procedure that can take many hours, requires preparation, may cause discomfort, and involves a recovery period. Lasting changes to the treated skin, such as scarring, discoloration, and disfigurement, can occur, and healing may take several weeks to months. For patients with multiple or recurring nodular BCCs, repeated procedures are required over time, which can become physically and emotionally demanding. Although surgery remains the primary treatment option for nodular BCC, it is not suitable for all basal cell carcinoma lesions or patients.

This underscores the need for treatments that preserve skin integrity and lead to better outcomes for patients.

 
Mohs Surgery
FLD-103 for Basal Cell Carcinoma

FLD-103: An Investigational Non-Surgical Treatment for nBCC by Feldan Therapeutics

Injected directly into nBCC tumors, FLD-103 is developed to preserve skin health and integrity while minimizing discomfort and disruption to patients' daily lives.

Skin Integrity

Administered through injections to preserve the health and appearance of skin

Minimal Recovery

Non-surgical procedure allows patients to get back to daily activities quickly

Reduced Time-to-Treatment

Available through more dermatology practices

Our cells use different signaling systems to guide how they grow and develop. In healthy adult skin, one of these systems—called the Hedgehog pathway—is usually switched off. In basal cell carcinoma, a change in the DNA causes this pathway to become abnormally active, sending signals that drive cancer cell growth.

FLD-103 has been developed to block a key component of this pathway, helping to slow or stop the abnormal growth of cancer cells.

FLD-103 Mechanism of Action

FLD-103 Clinical Trial Status

 FLD-103 is an investigational treatment currently being evaluated in clinical trials. It is not yet approved for general use.  

*This page provides patients and families with general information about the selected conditions we are addressing, as well as insights into our innovative therapies and how they are developed. The content is intended to be informative and supportive, and does not replace personalized medical advice. Our therapies are investigational products and have not been approved by the FDA. Their safety and efficacy have not been established. Any data presented are preliminary and subject to change until study completion and regulatory review.